News Related to Deutsche Bank

Related coverage linked through entity extraction aliases.

Deutsche Bank upgrades Merck to Buy, citing path beyond Keytruda patent cliff

Apr 22, 2026

Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.

AstraZeneca's Breztri Shows Positive Results in Phase III Asthma Trials

Mar 20, 2026

AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.